8-K: ImmuCell Reports Record First Quarter Sales and Net Income for 2025

ImmuCell Corporation announces an 11% increase in product sales and record net income for the first quarter of 2025.

Summary

• ImmuCell Corporation reported its unaudited financial results for the quarter ended March 31, 2025.
• Product sales increased by 11% to approximately $8.1 million compared to the first quarter of 2024.
• Net income reached a record high of approximately $1.4 million, surpassing the previous record of $584,000 set in the first quarter of 2017.
• The gross margin improved to 42% in the first quarter of 2025, compared to 37% in the fourth quarter of 2024.
• Adjusted EBITDA improved to approximately $2.3 million for the three-month period ended March 31, 2025.
• Cash and cash equivalents increased to $4.6 million as of March 31, 2025, from $3.8 million as of December 31, 2024.
• Net working capital increased to approximately $12.1 million as of March 31, 2025, from $10.6 million as of December 31, 2024.
• Stockholders' equity increased to $29 million as of March 31, 2025, from $27.5 million as of December 31, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record sales and net income, improved gross margins, and increased cash and equity; however, there are some concerns about backlog and contract manufacturer issues.

Positives

• Record product sales of $8.1 million for the first quarter of 2025.
• Record net income of $1.4 million for the first quarter of 2025.
• Improved gross margin of 42% for the first quarter of 2025.
• Increased cash and cash equivalents to $4.6 million as of March 31, 2025.
• Increased net working capital to $12.1 million as of March 31, 2025.
• Increased stockholders' equity to $29 million as of March 31, 2025.

Negatives

• The company is working to reduce the backlog of orders.
• A contract manufacturer is working to resolve inspectional observations at their facilities.
• The company is reducing product development expenses.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• These risks include difficulties or delays in product development, regulatory approval, and marketing.
• Competition within anticipated product markets and customer acceptance of new and existing products are also risks.
• Adverse impacts of supply chain disruptions on operations and customer/supplier relationships are a concern.
• Commercial and operational risks relating to the current and planned expansion of production capacity exist.

Future Outlook

The company is working to reduce the backlog of orders and improve its gross margin as it continues to manufacture at its new, higher level of production output; the company is also moving ahead with Investigational Product use of Re-Tain to collect market feedback and exploring potential strategic options for its technology.

Management Comments

• Product sales during the first quarter of 2025 of $8.1 million set a record high for us, beating the previous record set during the fourth quarter of 2024, commented Michael F. Brigham, President and CEO of ImmuCell.
• We also set a quarterly record for net income, which totaled approximately $1.4 million, beating the previous record of $584,000 set during the first quarter of 2017.
• As we continue to manufacture at our new, higher level of production output, we are working to reduce the backlog of orders and improve our gross margin, continued Mr. Brigham.
• As our contract manufacturer continues to work to resolve inspectional observations at their facilities, we are moving ahead with Investigational Product use of Re-Tain to collect market feedback about product performance in the field over the second half of 2025, concluded Mr. Brigham.

Industry Context

ImmuCell operates in the animal health industry, specifically focusing on products for dairy and beef cattle; the company's focus on improving animal health and productivity aligns with the broader industry trend of enhancing livestock management practices.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing ImmuCell's specific product lines and target markets in detail.
• However, companies like Zoetis, Elanco Animal Health, and Merck Animal Health are major players in the broader animal health market.
• ImmuCell's growth rates and margins would need to be compared against these larger companies and more direct competitors to assess its relative performance.
• For example, Zoetis often reports quarterly revenue growth in the single-digit percentages, so ImmuCell's 11% product sales growth is noteworthy.
• Similarly, gross margins for animal health companies typically range from 50% to 70%, so ImmuCell's 42% gross margin indicates room for improvement.

Stakeholder Impact

• Shareholders will likely react positively to the record sales and net income.
• Employees may benefit from the company's improved financial performance.
• Customers may experience improved product availability as the company works to reduce its backlog.

Next Steps

• The company plans to host a conference call on May 15, 2025, to discuss the financial results.
• The company will continue to work on reducing the backlog of orders.
• The company will continue to work with its contract manufacturer to resolve inspectional observations.
• The company will continue Investigational Product use of Re-Tain to collect market feedback.

Key Dates

Keywords

ImmuCell, financial results, product sales, net income, EBITDA, animal health, dairy cattle, beef cattle